GLPG - Galapagos N.V. Debt to Book Capitalization Ratio

Graphic logo of Galapagos N.V. (GLPG)

This daily price chart for Galapagos NV (GLPG) illustrates the price action of an asset whose pricing power in the EU is restricted by government regulators, with the current figure standing at 0.00. The business is exposed to the risk of a shift in development strategy and a potential severance of ties with major partners. However, its status as a reputable European brand in cell therapy and small molecules ensures Galapagos NV (GLPG) maintains steady trust among physicians.

GLPG (Galapagos Corp) Debt to Book Value history from 07/04/2022 to 05/08/2026
Core merchandise of Galapagos Genomics

This ratio compares the company's total liabilities to its equity, determining the degree of financial leverage and the overall stability of the balance sheet structure. By analyzing the debt of Galapagos NV (GLPG) relative to its book capitalization, an investor assesses the margin of safety for the development of the decentralized CAR-T platform under strict operational cost control and royalty dependence.

Competitors of Galapagos NV

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio ANIP (ANI Pharmaceuticals Inc)|MNKD: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio sxtchina.com (SXTC)|EPRX (Eupraxia Pharmaceuticals Inc.) - Debts to Book Capitalization|Debt to Net Assets BioHarvest Sciences, Inc. BHST|Invizyne Technologies, Inc. - Debts to Book Capitalization|ORMP: Debts to Book Capitalization|enterabio.com (ENTX) - Debt to Book Capitalization Ratio|ipatherapeutics.com (HYFT) - Debt to Book Capitalization Ratio|ABVC (ABVC BioPharma, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization CPIX|QNTM - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio FibroGen Corporation (FGEN)|Debts to Book Capitalization TELO (Telomir Pharmaceuticals)|Debts to Book Capitalization Rani Therapeutics Holdings RANI|Debts to Book Capitalization SNYR|RLYB: Debt to Net Assets|Debt to Book Capitalization Ratio LEXX|PULM (Pulmatrix Corporation) - Debts to Book Value|PTHL: Debt to Book Capitalization Ratio|Debts to Net Assets Aptorum (APM)|Lyra Therapeutics (LYRA) - Debt to Book Value|Debt to Net Assets Ratio IBO (Impact BioMedical, Inc.)|TNFA - Debt to Book Capitalization Ratio|YCBD - Debt to Book Value Ratio|PRFX - Debt to Book Value|CYTO - Debt to Book Capitalization Ratio|Debts to Book Capitalization LIPO (Lipella Pharmaceuticals, Inc.)|OPTN (OptiNose Inc) - Debt to Net Assets|Debt to Book Capitalization Ratio Pieris|Debt to Book Capitalization Ratio PROC|PTPI - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio qlsyy.net (QLI)|SLRN (ACELYRIN) - Debts to Book Capitalization|TFF Pharmaceuticals Inc. - Debt to Net Assets